Which Biotech Programs Will Survive?
Going Global: Takeda Paying $13.7B Cash for Nycomed
By Cormac Sheridan
Friday, May 20, 2011
Takeda Pharmaceutical Co. Ltd. is beefing up its presence in emerging markets and in Europe by paying $13.7 billion in cash for Nycomed GmbH, a privately held mid-sized pharma company.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.